Amyloid-beta
Amyloid-beta is the protein fragment that forms plaques in Alzheimer’s disease. Clearing it is the idea behind several antibodies.
Overview
Plaque reduction is now a measurable drug effect. Whether enough clinical benefit follows, for whom, is the practical question.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · Amyloid-beta is the protein fragment that forms plaques in Alzheimer’s disease. Clearing it is the idea behind several antibodies.
- 1 · What it is
Amyloid-beta is the protein fragment that forms plaques in Alzheimer’s disease. Clearing it is the idea behind several antibodies.
- 2 · What goes wrong in cancer
Peptides from amyloid precursor protein that aggregate into plaques.
- 3 · How drugs use it
3 products aim at Amyloid-beta: other agents. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Biology
Peptides from amyloid precursor protein that aggregate into plaques.
- Alzheimer’s disease cortex and vessel walls (CAA).
Donanemab is a monthly infused antibody for early Alzheimer’s disease after amyloid confirmation, with the same ARIA monitoring theme as other amyloid antibodies.
Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.
Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.
Latest papers
topQuery for this target: (TITLE:"Amyloid-beta" OR ABSTRACT:"Amyloid-beta" OR TITLE:"APP" OR ABSTRACT:"APP" OR TITLE:"Aβ" OR ABSTRACT:"Aβ") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Amyloid-beta, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyApoE testing
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- RoadmapAnti-amyloid medicines
Shares Remternetug, Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyEli Lilly
Shares Remternetug, Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetTau
Shares Amyloid and tau cascade (simplified), Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.